Breast Cancer Diagnostics Market Size, Share & Growth [2031]
Breast Cancer Diagnostics Market Size, Share & Growth [2031]
Segments - Breast Cancer Diagnostics Market By Types (Imaging, Biopsy, Genomic Tests, and Blood Tests), Products (Platform-based [Next-generation Sequencing, Microarrays, PCR, and Others] and Instrument-based [Imaging and Biopsy]), Applications (Screening, Diagnostic & Predictive, Prognostic, and Research), End-users (Hospitals & Clinics, Diagnostic Centers & Medical Laboratories, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023–2031
Upcoming
| Report ID :HC-791
| 4.7 Rating
| 67 Reviews
| 175 Pages
| Format :
Report Description
Breast Cancer Diagnostics Market Outlook 2031
The global breast cancer diagnostics market size was valued at USD 4.46 Billion in 2022 and is likely reach to USD 7.99 Billion by 2031, expanding at a CAGR of 6.7% during the forecast period, 2023 – 2031. The growth of the market is attributed to rising government efforts to raise cancer screening and diagnosis rates as well as the rising incidence of cancer.
Breast cancer occurs due to the disorderly expansion of the cells and tissues of the breast and appears as a lump surrounding the internal breast tissues, usually developing into a tumor. Breast cancer is a malignant tumor that almost exclusively affects women, with a few exceptions in adults. Breast cancer is now the most prevalent cancer in women all around the world.
The number of women diagnosed with breast cancer is on the rise. Therefore, it becomes necessary for the early detection of the breast cancer among women. Early detection of cancer increases the chances of preventing the progress of the cancer and increase the chance of survival of patients significantly. Breast cancer can be detected early due to raising awareness as well as encouraging early diagnosis and screening.
Breast Cancer Diagnostics Market Trends, Drivers, Restraints, and Opportunities:
- Increasing number of private diagnostic centers and development of innovative diagnostic imaging procedures are expected to boost the market expansion.
- Rising establishment of public hospitals and centers specialized for the treatment of cancer across the globe present key driving factors for the market.
- Growing demand for technologically advanced products that can improve accuracy, speed, and cost-effectiveness for cancer detection is propelling the market growth.
- Governments sponsored awareness activities and initiatives in developed countries encouraging and guiding primary care doctors to recommend cancer screening tests for patients are propelling the market expansion.
- Higher cost of diagnostics and lack of effective reimbursement rates, and budgetary restrictions among patients from developing countries are key challenges that can hamper the market growth.
Scope of Breast Cancer Diagnostics Market Report
The report on the global breast cancer diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Breast Cancer Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2022 |
|
Historic Data |
2016–2021 |
|
Forecast Period |
2023–2031 |
|
Segmentation |
Types (Imaging, Biopsy, Genomic Tests, and Blood Tests), Products (Platform-based [Next-generation Sequencing, Microarrays, PCR, and Others] and Instrument-based [Imaging and Biopsy]), Applications (Screening, Diagnostic & Predictive, Prognostic, and Research), End-Users (Hospitals & Clinics, Diagnostic Centers & Medical Laboratories, and Others), |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Hologic Inc.; Genomic Health (Exact Sciences Corporation); BD; Danaher; Koninklijke Philips N.V.; QIAGEN; Thermo Fisher Scientific Inc.; Myriad Genetics; Argon Medical Devices, Inc.; F. Hoffmann-La Roche Ltd. |
Breast Cancer Diagnostics Market Segment Insights
Imaging segment is expected to dominate the market
Based on types, the global breast cancer diagnostics market is segmented into imaging, biopsy, genomic tests, and blood tests. The Imaging segment held a dominant market share, representing over 70.3% in 2020 and is expected to continue the trend in the coming years.
The segment growth is attributed to factors such as large volume of procedures, easy accessibility, and enhanced effectiveness of imagining technology. Mammograms, ultrasound, and magnetic resonance imaging (MRI) are some of the most common imaging techniques used for screening and diagnosis.
Furthermore, a number of advanced new imaging techniques for breast cancer diagnosis such as breast tomosynthesis, Molecular Breast Imaging (MBI), CT, and PET, are poised to change the landscape of breast imaging segment. On the other hand, the blood test segment is expected to grow significantly during the forecast period due to growing research studies carried out by the research organizations and major players to ensure high efficacy of liquid biopsy tests.
Instrument-based testing segment to hold a key share market
On the basis of products, the market is bifurcated into platform-based and instrument-based. The platform-based segment is further segmented into next-generation sequencing, microarrays, PCR, and others.
The instrument-based segment is also further segmented into imaging and biopsy. The instrument-based testing segment is expected to dominate the market, accounting for more than 70.2% in 2020. The segment growth is due to wide adoption of imaging devices as the first choice for general population-based screening of breast cancer patients.
All patients with breast cancer undergo a biopsy to confirm their diagnosis. Many organizations, such as the National Breast Cancer Foundation, Inc., are working to raise awareness about breast cancer, the importance of early detection, and treatment options.
On the other hand, the platform-based products segment is anticipated to expand at a rapid pace during the forecast period due to innovation of the products and the higher preference of such products for targeted therapy.
Diagnostics & predictive segment to constitute a large share
Based on applications, the global breast cancer diagnostics market is segmented into screening, diagnostic & predictive, prognostic, and research. The diagnostics & predictive segment is anticipated to constitute a dominant market share representing with an impressive CAGR during the forecast period due to the increasing prevalence of genetic testing.
Meanwhile, the prognostic segment is anticipated to expand at a significant growth rate during the forecast period as these tests are used to match patients with therapies, they are becoming more important.
Hospitals & clinics segment to register a robust CAGR
On the basis of end-users, the market is segmented into hospitals & clinics, diagnostic centers & medical laboratories, and others. The hospitals & clinics segment is expected to register a robust CAGR during the forecast period owing to increasing hospitalization of patients and the growing load of the disease.
Patients usually prefer to undergo biopsy for confirmatory testing in hospitals after the screening test. Additionally, PET, CT, and MRI are used to track disease progression and determine the efficacy of cancer treatments.
Diagnostic centers & medical laboratories segment, however, is anticipated to grow significantly during the forecast period due to a rise in the number of government initiatives to provide different services, such as diagnostic test reimbursement.
Breast Cancer Diagnostics Market Regional Outlook
North America is likely to dominate the market
In terms of regions, the global breast cancer diagnostics market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is likely to dominate the market due to factors such as the presence of major players, well-established diagnostic and screening infrastructure, technological advances, high patient knowledge, and favorable reimbursement policies.
Meanwhile, the market in Asia Pacific segment is expected to grow at a rapid pace during the forecast period. The regional market growth is due to the incidence of breast cancer and the adoption of advanced diagnostic techniques among the patients in the region.
Furthermore, growing easy policy of reimbursement guidelines and expanding healthcare infrastructure from governments present key factors pushing the market expansion.
Segments
Types
- Imaging
- Biopsy
- Genomic Tests
- Blood Tests
- Others
Products
- Platform-based Products
- Next-generation Sequencing
- Microarrays
- PCR
- Others
- Instrument-based Products
- Imaging
- Biopsy
Applications
- Screening
- Diagnostic & Predictive
- Prognostic
- Research
End-Users
- Hospitals & Clinics
- Diagnostic Centers & Medical Laboratories
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Hologic Inc.
- Genomic Health (Exact Sciences Corporation)
- BD
- Danaher
- Koninklijke Philips N.V.
- QIAGEN
- Thermo Fisher Scientific Inc.
- Myriad Genetics
- Argon Medical Devices, Inc.
- F. Hoffmann-La Roche Ltd.
Competitive Landscape
Some of the major companies competing in the market are Hologic Inc.; Genomic Health (Exact Sciences Corporation); BD; Danaher; Koninklijke Philips N.V.; QIAGEN; Thermo Fisher Scientific Inc.; Myriad Genetics; Argon Medical Devices, Inc.; F. Hoffmann-La Roche Ltd.
Several market strategies such as mergers, acquisitions, and alliances are being used by major corporations to increase their global market share. Hologic Inc. acquired Biotheranostics and SOMATEX Medical Technologies GmbH in January 2021. Thermo Fisher Scientific, Inc. negotiated a partnership with AstraZeneca and the University of Nebraska Medical Center in September 2020 to develop innovative clinical biomarkers. In addition, the firm signed an agreement with Pfizer, Inc. in October 2018 to use BRACAnalysis CDx as a companion diagnostic with Pfizer's patented talazoparib.
Table Of Content
1. Executive Summary2. Assumptions and Acronyms Used
3. Research Methodology
4. Breast Cancer Diagnostics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Breast Cancer Diagnostics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Breast Cancer Diagnostics Market - Supply Chain
4.5. Global Breast Cancer Diagnostics Market Forecast
4.5.1. Breast Cancer Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Breast Cancer Diagnostics Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Breast Cancer Diagnostics Market Absolute $ Opportunity
5. Global Breast Cancer Diagnostics Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Breast Cancer Diagnostics Market Size and Volume Forecast by Types
5.3.1. Imaging
5.3.2. Biopsy
5.3.3. Genomic Tests
5.3.4. Blood Tests
5.3.5. Others
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Breast Cancer Diagnostics Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
6.3.1. Screening
6.3.2. Diagnostic & Predictive
6.3.3. Prognostic
6.3.4. Research
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Breast Cancer Diagnostics Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
7.3.1. Hospitals & Clinics
7.3.2. Diagnostic Centers & Medical Laboratories
7.3.3. Others
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Breast Cancer Diagnostics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Breast Cancer Diagnostics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
9. North America Breast Cancer Diagnostics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Breast Cancer Diagnostics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Breast Cancer Diagnostics Market Size and Volume Forecast by Types
9.4.1. Imaging
9.4.2. Biopsy
9.4.3. Genomic Tests
9.4.4. Blood Tests
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
9.7.1. Screening
9.7.2. Diagnostic & Predictive
9.7.3. Prognostic
9.7.4. Research
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
9.10.1. Hospitals & Clinics
9.10.2. Diagnostic Centers & Medical Laboratories
9.10.3. Others
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
10. Latin America Breast Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Breast Cancer Diagnostics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Breast Cancer Diagnostics Market Size and Volume Forecast by Types
10.4.1. Imaging
10.4.2. Biopsy
10.4.3. Genomic Tests
10.4.4. Blood Tests
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
10.7.1. Screening
10.7.2. Diagnostic & Predictive
10.7.3. Prognostic
10.7.4. Research
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
10.10.1. Hospitals & Clinics
10.10.2. Diagnostic Centers & Medical Laboratories
10.10.3. Others
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
11. Europe Breast Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Breast Cancer Diagnostics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Breast Cancer Diagnostics Market Size and Volume Forecast by Types
11.4.1. Imaging
11.4.2. Biopsy
11.4.3. Genomic Tests
11.4.4. Blood Tests
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
11.7.1. Screening
11.7.2. Diagnostic & Predictive
11.7.3. Prognostic
11.7.4. Research
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
11.10.1. Hospitals & Clinics
11.10.2. Diagnostic Centers & Medical Laboratories
11.10.3. Others
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
12. Asia Pacific Breast Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Breast Cancer Diagnostics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Breast Cancer Diagnostics Market Size and Volume Forecast by Types
12.4.1. Imaging
12.4.2. Biopsy
12.4.3. Genomic Tests
12.4.4. Blood Tests
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
12.7.1. Screening
12.7.2. Diagnostic & Predictive
12.7.3. Prognostic
12.7.4. Research
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
12.10.1. Hospitals & Clinics
12.10.2. Diagnostic Centers & Medical Laboratories
12.10.3. Others
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
13. Middle East & Africa Breast Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa Breast Cancer Diagnostics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Breast Cancer Diagnostics Market Size and Volume Forecast by Types
13.4.1. Imaging
13.4.2. Biopsy
13.4.3. Genomic Tests
13.4.4. Blood Tests
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa Breast Cancer Diagnostics Market Size and Volume Forecast by Applications
13.7.1. Screening
13.7.2. Diagnostic & Predictive
13.7.3. Prognostic
13.7.4. Research
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa Breast Cancer Diagnostics Market Size and Volume Forecast by End Users
13.10.1. Hospitals & Clinics
13.10.2. Diagnostic Centers & Medical Laboratories
13.10.3. Others
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa Breast Cancer Diagnostics Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global Breast Cancer Diagnostics Market: Market Share Analysis
14.2. Breast Cancer Diagnostics Distributors and Customers
14.3. Breast Cancer Diagnostics Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. Hologic Inc.
14.4.2. Genomic Health (Exact Sciences Corporation)
14.4.3. BD
14.4.4. Danaher
14.4.5. Koninklijke Philips N.V.
14.4.6. QIAGEN
14.4.7. Thermo Fisher Scientific Inc.
14.4.8. Myriad Genetics
Methodology
Related Reports
Some other reports from this category!
Our Clients
